A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets
- PMID:36217030
- PMCID: PMC9851973
- DOI: 10.1038/s41587-022-01474-0
A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets
Abstract
Studying viral-host protein-protein interactions can facilitate the discovery of therapies for viral infection. We use high-throughput yeast two-hybrid experiments and mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of 739 high-confidence binary and co-complex interactions, validating 218 known SARS-CoV-2 host factors and revealing 361 novel ones. Our results show the highest overlap of interaction partners between published datasets and of genes differentially expressed in samples from COVID-19 patients. We identify an interaction between the viral protein ORF3a and the human transcription factor ZNF579, illustrating a direct viral impact on host transcription. We perform network-based screens of >2,900 FDA-approved or investigational drugs and identify 23 with significant network proximity to SARS-CoV-2 host factors. One of these drugs, carvedilol, shows clinical benefits for COVID-19 patients in an electronic health records analysis and antiviral properties in a human lung cell line infected with SARS-CoV-2. Our study demonstrates the value of network systems biology to understand human-virus interactions and provides hits for further research on COVID-19 therapeutics.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests
The authors declare no competing interests.
Figures









Update of
- A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.Zhou Y, Liu Y, Gupta S, Paramo MI, Hou Y, Mao C, Luo Y, Judd J, Wierbowski S, Bertolotti M, Nerkar M, Jehi L, Drayman N, Nicolaescu V, Gula H, Tay S, Randall G, Lis JT, Feschotte C, Erzurum SC, Cheng F, Yu H.Zhou Y, et al.Res Sq [Preprint]. 2022 Jun 7:rs.3.rs-1354127. doi: 10.21203/rs.3.rs-1354127/v2.Res Sq. 2022.Update in:Nat Biotechnol. 2023 Jan;41(1):128-139. doi: 10.1038/s41587-022-01474-0.PMID:35677070Free PMC article.Updated.Preprint.
Similar articles
- A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.Zhou Y, Liu Y, Gupta S, Paramo MI, Hou Y, Mao C, Luo Y, Judd J, Wierbowski S, Bertolotti M, Nerkar M, Jehi L, Drayman N, Nicolaescu V, Gula H, Tay S, Randall G, Lis JT, Feschotte C, Erzurum SC, Cheng F, Yu H.Zhou Y, et al.Res Sq [Preprint]. 2022 Jun 7:rs.3.rs-1354127. doi: 10.21203/rs.3.rs-1354127/v2.Res Sq. 2022.Update in:Nat Biotechnol. 2023 Jan;41(1):128-139. doi: 10.1038/s41587-022-01474-0.PMID:35677070Free PMC article.Updated.Preprint.
- Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.Terracciano R, Preianò M, Fregola A, Pelaia C, Montalcini T, Savino R.Terracciano R, et al.Int J Mol Sci. 2021 Jan 7;22(2):532. doi: 10.3390/ijms22020532.Int J Mol Sci. 2021.PMID:33430309Free PMC article.Review.
- COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection.Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G; COVID 19 INMI Network Medicine for IDs Study Group.Messina F, et al.J Transl Med. 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w.J Transl Med. 2020.PMID:32522207Free PMC article.
- Integrated interactome and transcriptome analysis reveals key host factors critical for SARS-CoV-2 infection.Sheng J, Li L, Lv X, Gao M, Chen Z, Zhou Z, Wang J, Wu A, Jiang T.Sheng J, et al.Virol Sin. 2023 Aug;38(4):508-519. doi: 10.1016/j.virs.2023.05.004. Epub 2023 May 9.Virol Sin. 2023.PMID:37169126Free PMC article.
- The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.Marchi R, Sugita B, Centa A, Fonseca AS, Bortoletto S, Fiorentin K, Ferreira S, Cavalli LR.Marchi R, et al.Infect Genet Evol. 2021 Jul;91:104832. doi: 10.1016/j.meegid.2021.104832. Epub 2021 Apr 1.Infect Genet Evol. 2021.PMID:33812037Free PMC article.
Cited by
- Mapping protein-protein interactions by mass spectrometry.Liu X, Abad L, Chatterjee L, Cristea IM, Varjosalo M.Liu X, et al.Mass Spectrom Rev. 2024 May 14:10.1002/mas.21887. doi: 10.1002/mas.21887. Online ahead of print.Mass Spectrom Rev. 2024.PMID:38742660Review.
- Bioinformatics Goes Viral: I. Databases, Phylogenetics and Phylodynamics Tools for Boosting Virus Research.Vello F, Filippini F, Righetto I.Vello F, et al.Viruses. 2024 Sep 6;16(9):1425. doi: 10.3390/v16091425.Viruses. 2024.PMID:39339901Free PMC article.Review.
- Understanding the molecular mechanisms of human diseases: the benefits of fission yeasts.Acs-Szabo L, Papp LA, Miklos I.Acs-Szabo L, et al.Microb Cell. 2024 Aug 2;11:288-311. doi: 10.15698/mic2024.08.833. eCollection 2024.Microb Cell. 2024.PMID:39104724Free PMC article.
- In silico protein function prediction: the rise of machine learning-based approaches.Chen J, Gu Z, Lai L, Pei J.Chen J, et al.Med Rev (2021). 2023 Nov 29;3(6):487-510. doi: 10.1515/mr-2023-0038. eCollection 2023 Dec.Med Rev (2021). 2023.PMID:38282798Free PMC article.Review.
- Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2.Wang W, Hu Y, Li B, Wang H, Shen J.Wang W, et al.Biochem Pharmacol. 2023 Feb;208:115401. doi: 10.1016/j.bcp.2022.115401. Epub 2022 Dec 30.Biochem Pharmacol. 2023.PMID:36592707Free PMC article.Review.
References
- Stukalov A et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 594, 246–252 (2021). - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
- U01 HG009391/HG/NHGRI NIH HHS/United States
- R56 AG074001/AG/NIA NIH HHS/United States
- R01 HL060917/HL/NHLBI NIH HHS/United States
- R01 DK115398/DK/NIDDK NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- U01 AG073323/AG/NIA NIH HHS/United States
- R01 AG066707/AG/NIA NIH HHS/United States
- R01 GM124559/GM/NIGMS NIH HHS/United States
- RM1 GM139738/GM/NIGMS NIH HHS/United States
- UM1 HG009393/HG/NHGRI NIH HHS/United States
- R37 HL060917/HL/NHLBI NIH HHS/United States
- R35 GM122550/GM/NIGMS NIH HHS/United States
- R01 AG076448/AG/NIA NIH HHS/United States
- R01 GM125639/GM/NIGMS NIH HHS/United States
- R01 GM130885/GM/NIGMS NIH HHS/United States
- F31 HG010820/HG/NHGRI NIH HHS/United States
- R01 LM013337/LM/NLM NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous